key: cord-0859869-wozfrrqa authors: Mado, Hubert; Adamczyk-Sowa, Monika title: Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations date: 2021-04-16 journal: J Neurol DOI: 10.1007/s00415-021-10547-0 sha: 099797db3a2ea8f8764db1ad96a4838cbe3f463a doc_id: 859869 cord_uid: wozfrrqa nan Detailed case report is in preparation as a separate publication. The most essential information for the purposes of this commentary is presented below. A woman aged 23 with PPMS diagnosed according to the McDonald 2017 criteria in 2019 and treated since then with ocrelizumab according to the manufacturer's recommendations was given Pfizer COVID-19 mRNA vaccine. The vaccination was conducted within the timeframe consistent with the statement of the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society [6] . The patient had never been diagnosed with COVID-19, nor had she reported signs or symptoms that might have suggested such a diagnosis since the beginning of the COVID-19 pandemic. In this patient, the immune response to COVID-19 vaccination was obtained, as confirmed by quantitative detection of antibodies to the SARS-CoV-2 S protein receptor-binding domain performed more than 4 weeks after the second dose of the vaccine in laboratories accredited by the Polish Centre for Accreditation. Our patient was vaccinated in accordance with the statement issued by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society, which indicates that vaccination should be given 4-6 months after the last dose of ocrelizumab and should be completed at least 4-6 weeks before another dose of the drug [6] . The immune antibody response was observed in this patient. In view of the data presented by Khayat Khoei et al., this seems to be due to well-timed intervals between the last dose of ocrelizumab before vaccination and another infusion following the second dose of the vaccine [1] . Khayat Khoei et al. presented the case of the patient who had negative antibody response and was given another dose of ocrelizumab 9 days after the second dose of the vaccine, which from an immunological point of view may seem too short a period [1, [6] [7] [8] . Considering the patient we presented and the effective post-vaccination response, it seems that the reason for no response after vaccination in the patient reported by Khayat Khoei et al. may be related to the fact that the time window from the second dose of the vaccine to the next ocrelizumab infusion might have been too short, which should be at least 4-6 weeks [6] [7] [8] . Therefore, it seems reasonable to strongly suggest the adequate time frame between ocrelizumab infusion and vaccination [6] . However, further reports are warranted to confirm the validity of our observations. Funding This paper received no grant from any funding agency in the public, commercial, or not-for-profit sectors. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society Ocrevus : EPAR-Product Information; Annex I-Summary of product characteristics B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran The authors declare that there is no conflict of interest.